The TrAIbe

Artificial Intelligence: Human-Centric Regulation sets the stage for Sustainable Innovation

Artificial Intelligence technologies and uses are being developed at an exponential rate, and consequently, market demands keep growing. How does this affect our personal and professional lives? Could a human-centric approach make the difference in how we see the relationship between human intelligence and artificial intelligence? Let's take a look together.

Human-centric AI for Pharma & Life Sciences
4 min reading

We often cover topics revolving around the power of Artificial Intelligence, diving deeper into the benefits it can bring to our private and professional lives, as well as different markets. At the same time, we stress the importance of understanding the potential of these new technologies, reminding everyone that human intelligence always has the last say.

In our previous blog we highlighted how the last principal makes a huge difference, even in regard to Tech companies developing their solutions (if you haven't done so yet, take a look behind the scenes): this time we decided to explore the intricate relationship between AI and Human Being as its user, his protection, always hinting at our reference markets, Pharma & Life Sciences.

As an IT company, we can't but start from data, especially to introduce the focus of this article: in the Italian market, there seems to be no stopping to Artificial Intelligence growth. According to a research conducted by the Artificial Intelligence Observatory of the School of Management, Politecnico of Milan, in 2023 Italy saw AI grow to 52%, with an economic value of € 760 million, against 32% growth in 2022. This data surely corroborates the great potential lying in these new technologies which, as of today, have found and will continue to find implementation in different industries.

A reader's who keeps watchful eyes on topics related to digital transformation, will probably know that an exponential growth without needed control could, even if not preferred, display potential risks: it's no surprise that, according to the research above, 77% of Italians still worries, to some extent, about AI and the role it could play in future innovation.

We don't have a one-size-fits-all answer to these doubts, Artificial Intelligence and its applications shift constantly and are, by nature, difficult to foresee; however, what we can do is acknowledge its potentials, understand it, and define boundaries in the Human and Technology relationship.

AI Act and the mindful use of technology: setting the stage for sustainable growth

As mentioned, the pace at which new AI technologies appear and their place as protagonists in the market didn’t go unnoticed by the European Union. We are talking about the AI Act: the law on Artificial Intelligence approved by the European Parliament on March 2024, aimed at guaranteeing the safety and respect the fundamental rights, as well as the sustainability of these technologies, promoting innovation.

We won't go too much into detail, considering the AI Act is now being verified, but we can already see the goal and commitment the European Union wants to pursue.  

By dividing Artificial Intelligence on a scale based on potential risks, this law sets the stage to supervise and protect citizens against all those AI "high risk" uses which could threaten their fundamental rights, while supporting and establishing an approach based on transparency for all those other uses which don't fall in the high-risk scale.

A significant element that transpires is exactly what we were talking about in the introduction of the article: the AI Act is not intended to put a stop to technology innovation, nor to AI itself. The human-centric approach, based on protecting people who come in contact with AI, is blended with comprehension on the makings these technologies can bring, supporting their sustainable growth.

How does all of the above apply to markets as regulated as Pharma and Life Sciences?

The answer lies in relying on a tech partner with substantial experience in Pharma and Life Sciences, capable of understanding needs, develop verticalized solutions which adapt to market shifts, while facilitating change management processes necessary to welcome these technologies and the innovation they bring.

In Trueblue, the human factor pushes us to look for improvements in our solutions, listening to feedback from our clients to better understand and answer specific needs of companies and people, as well as the market. The great opportunities AI brings in reaching a competitive advantage and different commercial and business goals are real, just as much as people using and coming in contact with our solutions.

The very same attention towards regulatory and compliance requirements in AI needs to be followed and implemented in those solutions useful for Pharma and Life Science.

That's why AiDEA Event, our software for event management in Pharma and Life Sciences markets, was developed not only to enable an agile way of working, managing the entire strategy and improve cross-team collaboration in a unified platform; but also to let you interact with your audience while following markets regulatory requirements thanks to an integrated automatic compliance control system.

Discover how AiDEA Event revolutionized and propelled our clients to success by reading their stories, download the case study!

Your contact info
Once you’ve provided your data, one of our experts will get in touch.